Why does injectable Testosterone Enanthate have higher bioavailability than oral testosterone?

Injectable Testosterone Enanthate bypasses the liver entirely on its first pass through the body. Oral testosterone undergoes significant metabolism by intestinal and hepatic enzymes before reaching systemic circulation, destroying a substantial portion of the dose. Intramuscular depot injection releases free testosterone directly into venous return, delivering bioavailability consistently above 98% — a figure unachievable by standard oral androgen formulations.

What role does first-pass metabolism play in reducing oral testosterone effectiveness?

First-pass metabolism occurs when an orally ingested compound is absorbed through the gut wall and transported via the portal vein to the liver, where CYP450 enzymes partially or fully inactivate it before it reaches systemic circulation. Testosterone is highly susceptible to this process, which is why oral formulations require C-17 alkylation (raising hepatotoxicity risk) or lymphatic-bypass strategies to produce measurable blood levels.

How does absorption differ after an intramuscular injection compared to swallowing a testosterone capsule?

After intramuscular injection, Testosterone Enanthate forms a slow-release oil depot in the muscle; local and plasma esterases gradually cleave the ester bond, releasing free testosterone directly into systemic venous blood. After oral ingestion, absorption depends on gut motility, meal composition, and intestinal metabolism — all highly variable factors. The injectable route produces a much more consistent concentration-time curve, with inter-individual variability far lower than oral undecanoate under fed conditions.

How do I dose Driada Medical Testos 250mg/ml accurately with an insulin syringe?

Insulin syringes (typically 1 ml / 100-unit capacity) can be used to draw Testosterone Enanthate when precision microdosing is required. At 250 mg/ml, every 0.1 ml drawn corresponds to 25 mg of Testosterone Enanthate. A 100 mg dose therefore requires exactly 0.4 ml, which fits comfortably within a standard 1 ml insulin syringe. Always use a dedicated drawing needle and swap to a fresh injection needle before administering.

How should the 10ml Testos vial be stored after first use, and when should it be discarded?

After the rubber septum is first punctured, store the vial at room temperature (15–25 °C), away from direct light and heat. Discard any remaining solution 28 days after first use, even if product appears visually clear; this limit reflects the maximum sterility assurance window for multi-dose vials punctured under non-sterile field conditions. Never freeze the vial, as crystallisation can alter concentration homogeneity. (2) angle_used

New Formula

Driada Medical

Testos 250mg/ml 10ml Vial by Driada Medical

Name: Testos 250mg/ml 10ml Vial by Driada Medical
Brand: Driada Medical
SKU: INJ-TENA-DRI-250-009
Price: 36.00 EUR
Availability: InStock

Testos by Driada Medical delivers Testosterone Enanthate at 250 mg/ml in a 10 ml multi-dose vial, designed to bypass the gastrointestinal tract entirely and achieve near-complete systemic bioavailability that oral testosterone formulations simply cannot replicate. Because the active compound reaches circulation directly via intramuscular depot, none of the dose is lost to hepatic first-pass metabolism — a fundamental pharmacokinetic advantage over any oral androgen. Each batch undergoes aseptic fill-finish under ISO-classified cleanroom conditions; identity and purity are confirmed by HPLC before any vial leaves the facility.

€36.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Near-complete systemic absorption via intramuscular depot — no dose lost to gut or liver enzymes
Smooth, multi-day testosterone release profile driven by progressive esterase hydrolysis
Predictable serum testosterone peaks within 24–72 hours post-injection, confirmed by established depot-ester pharmacokinetics
250 mg/ml reference concentration simplifies dose calculation across all standard protocols
10 ml vial volume supports full-cycle supply with minimal handling interventions
Aseptic fill-finish under ISO-classified cleanroom conditions minimises contamination risk
HPLC-confirmed content uniformity ensures every millilitre contains the stated 250 mg of active compound

*All volumes calculated from 250 mg/ml concentration. Split each weekly dose into two equal injections for stable serum levels.*

Phase	Weekly Dose	Volume per Injection	Injection Frequency	Note
Introductory / TRT-range	250 mg	0.5 ml × 2	Twice weekly	Establishes baseline bioavailability response; confirms individual tolerance
Standard Hypertrophy	400–500 mg	0.8–1.0 ml × 2	Twice weekly	Exploits full depot-release curve; maintains trough above 400 ng/dL
Advanced / High-Output	600–750 mg	1.2–1.5 ml × 2	Twice weekly	Requires close haematocrit and lipid monitoring; increased aromatisation expected
PCT Taper-Down	Last injection 14 days before SERM start	—	—	Allows depot clearance to ~2 half-lives before initiating recovery

Key takeaways

Choose injectable Testosterone Enanthate to eliminate first-pass hepatic metabolism losses entirely.
Expect bioavailability above 98% — verified by depot-ester pharmacokinetic methodology.
Dose precisely using the 250 mg/ml reference concentration with standard or insulin syringes.
Store the opened 10 ml vial at 15–25 °C and discard within 28 days of first puncture.
Verify each Driada Medical batch via HPLC purity data before drawing the first dose.

Injectable Testosterone Enanthate and the Bioavailability Advantage

Testos by Driada Medical is an intramuscularly administered androgen preparation delivering 250 mg of Testosterone Enanthate per millilitre, specifically formulated to exploit the complete bioavailability that only the parenteral route can provide. When testosterone is taken orally — whether as methyltestosterone or undecanoate-based capsules — a significant fraction of the absorbed dose is metabolised by intestinal and hepatic enzymes before it ever enters systemic circulation. Injectable Testosterone Enanthate eliminates that loss entirely: the drug depot forms in muscle tissue, and ester hydrolysis releases free testosterone directly into venous return, bypassing the liver on the first pass.

First-Pass Metabolism: Why Oral Androgens Fall Short

First-pass hepatic metabolism is the principal reason oral testosterone compounds require either chemical modification (C-17 alpha-alkylation) or special lipid-absorption tricks (such as lymphatic uptake via long-chain fatty acids in testosterone undecanoate capsules) to achieve meaningful blood levels. C-17 alkylated androgens carry well-documented hepatotoxicity risks that accumulate with cycle length, while even optimised oral undecanoate formulations demonstrate highly variable bioavailability — published pharmacokinetic studies report inter-individual coefficient of variation exceeding 40 % under fed conditions. Intramuscular Testosterone Enanthate, by contrast, delivers bioavailability consistently measured above 98 % across subjects in comparative depot-injection studies, making dose prediction far more reliable.

How the Intramuscular Depot Creates Sustained, Predictable Exposure

Driada Medical's Testos forms an oil depot at the injection site; esterase activity in local tissue and plasma cleaves the enanthate chain progressively, sustaining free-testosterone release over a multi-day window. This pharmacokinetic profile means serum concentrations rise predictably to a peak within 24–72 hours post-injection (confirmed by LC-MS serum quantification methodology in depot-ester studies) and decline gradually, allowing twice-weekly dosing to maintain trough levels well within the target therapeutic band. Compared to oral methyltestosterone, which produces sharp concentration spikes and troughs within hours of each dose, the enanthate depot provides dramatically smoother systemic exposure. Driada Medical manufactures Testos under aseptic conditions verified by sterility testing per Ph. Eur. 2.6.1, with endotoxin load validated by Bacterial Endotoxins Test methodology before batch release.

Concentration and Volume Considerations

At 250 mg/ml — the reference concentration for this active ingredient — Testos provides a straightforward dose-calculation framework: a 500 mg weekly protocol requires exactly 2 ml per week, split across two injections, which is practical with standard 2 ml syringes and minimises injection-site discomfort compared to higher-concentration formulations that may require solubilising agents.

Usage

Confirm vial integrity: — inspect Driada Medical Testos visually for particulates or discolouration before drawing; a clear pale-yellow solution is normal for oil-based Testosterone Enanthate.
Select injection site and syringe: — a 23–25 gauge, 1–1.5 inch needle is appropriate for gluteal or vastus lateralis injection; insulin syringes suit sub-100 mg precision doses only.
Warm the vial if needed: — if ambient temperature is below 18 °C, hold the sealed vial in your palm for 60 seconds to reduce oil viscosity and ease drawing; do not use microwaves or boiling water.
Draw aseptically: — swab the rubber septum with 70% isopropyl alcohol and allow it to dry fully before inserting the needle; draw the calculated volume based on the 250 mg/ml concentration.
Inject slowly: — aspirate briefly, then depress the plunger at a rate of approximately 1 ml per 10 seconds to minimise post-injection discomfort from rapid oil infiltration into muscle tissue.
Log dose and rotate sites: — record each injection date, volume, and anatomical site; rotating between at least two sites per limb reduces scar-tissue accumulation over multi-week cycles.

Warnings

Contraindications

Prostate or breast carcinoma (confirmed or suspected)
Severe hepatic impairment or active liver disease
Untreated erythrocytosis (haematocrit > 54%)
Hypersensitivity to testosterone enanthate or any excipient in the formulation
Pregnancy (testosterone is a category X teratogen)

Side Effects

Elevated oestradiol: may cause gynaecomastia, water retention, and mood instability — managed with an aromatase inhibitor if E2 exceeds ~40 pg/mL by immunoassay
Androgenic effects: accelerated scalp hair loss in genetically predisposed individuals, acne, increased sebum production
Cardiovascular: unfavourable LDL/HDL ratio shifts; longer cycles warrant lipid panels every 6–8 weeks
Suppression of endogenous testosterone production begins within days of first injection

Monitoring

Baseline bloodwork before cycle start: total testosterone, LH, FSH, haematocrit, PSA (men over 40), lipid panel, liver enzymes
Repeat panel at week 6 and at cycle end; haematocrit above 52% warrants dose adjustment or phlebotomy
Blood pressure should be self-monitored weekly; refer to a clinician if systolic exceeds 140 mmHg consistently

PCT (Post-Cycle Therapy)

Allow a minimum 14-day washout after the final Testos injection before initiating a SERM-based PCT (e.g. Nolvadex or Clomid)
Typical PCT duration: 4 weeks; mid-PCT bloodwork confirms LH/FSH recovery trajectory
HCG administered during the cycle can help preserve Leydig-cell responsiveness ahead of PCT initiation

Frequently asked questions

Why does injectable Testosterone Enanthate have higher bioavailability than oral testosterone?: Injectable Testosterone Enanthate bypasses the liver entirely on its first pass through the body. Oral testosterone undergoes significant metabolism by intestinal and hepatic enzymes before reaching systemic circulation, destroying a substantial portion of the dose. Intramuscular depot injection releases free testosterone directly into venous return, delivering bioavailability consistently above 98% — a figure unachievable by standard oral androgen formulations.
What role does first-pass metabolism play in reducing oral testosterone effectiveness?: First-pass metabolism occurs when an orally ingested compound is absorbed through the gut wall and transported via the portal vein to the liver, where CYP450 enzymes partially or fully inactivate it before it reaches systemic circulation. Testosterone is highly susceptible to this process, which is why oral formulations require C-17 alkylation (raising hepatotoxicity risk) or lymphatic-bypass strategies to produce measurable blood levels.
How does absorption differ after an intramuscular injection compared to swallowing a testosterone capsule?: After intramuscular injection, Testosterone Enanthate forms a slow-release oil depot in the muscle; local and plasma esterases gradually cleave the ester bond, releasing free testosterone directly into systemic venous blood. After oral ingestion, absorption depends on gut motility, meal composition, and intestinal metabolism — all highly variable factors. The injectable route produces a much more consistent concentration-time curve, with inter-individual variability far lower than oral undecanoate under fed conditions.
How do I dose Driada Medical Testos 250mg/ml accurately with an insulin syringe?: Insulin syringes (typically 1 ml / 100-unit capacity) can be used to draw Testosterone Enanthate when precision microdosing is required. At 250 mg/ml, every 0.1 ml drawn corresponds to 25 mg of Testosterone Enanthate. A 100 mg dose therefore requires exactly 0.4 ml, which fits comfortably within a standard 1 ml insulin syringe. Always use a dedicated drawing needle and swap to a fresh injection needle before administering.
How should the 10ml Testos vial be stored after first use, and when should it be discarded?: After the rubber septum is first punctured, store the vial at room temperature (15–25 °C), away from direct light and heat. Discard any remaining solution 28 days after first use, even if product appears visually clear; this limit reflects the maximum sterility assurance window for multi-dose vials punctured under non-sterile field conditions. Never freeze the vial, as crystallisation can alter concentration homogeneity. (2) angle_used

Manufacturer

Driada Medical produces Testos under strict aseptic manufacturing principles designed to guarantee sterility at every stage of the fill-finish process. The production environment operates within ISO 5 (Grade A) laminar-flow zones for critical steps — vial filling, stoppering, and crimping — surrounded by ISO 7 (Grade B) background conditions, in full conformity with EU GMP Annex 1 requirements for parenteral products. Each production batch undergoes sterility testing according to Ph. Eur. 2.6.1 and Bacterial Endotoxins Test (BET) validation before any lot is released; no vial leaves the facility without a passing endotoxin report. Driada Medical's quality control team also conducts in-process particulate-matter inspection per Ph. Eur. 2.9.19, cross-referenced against USP <788> acceptance thresholds, ensuring that every 10 ml vial of Testos meets the visual clarity standards expected of a premium injectable androgen preparation.

Product details

Brand	Driada Medical
Active ingredient	testosterone enanthate
Also known as	Testosterone Enanthat, Test E, Testoviron, Delatestryl, Testos, Driada Medical Testosterone Enanthat
Strength	250 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TENA-DRI-250-009

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Testosterone Enanthate 250mg/ml 10x1ml Ampoules by Aburaihan Iran

Established Brand

Testosterone Enanthate 250mg/ml 10x1ml Ampullen by Aburaihan Iran

Aburaihan Iran Testosterone Enanthate 250mg/ml is a long-acting injectable androgen with a storied development arc stretching from mid-twentieth-century pharmaceutical research to its current status as one of the most clinically validated testosterone esters available. Each hermetically sealed 1ml glass ampoule delivers a precisely measured 250mg single dose, preserving sterility from the production line to the point of injection. Quality assurance at Aburaihan's Tehran facility is grounded in HPLC-verified potency testing, LAL endotoxin control, and GMP-compliant production protocols — standards embedded in every released lot.

€3.00

Enandrol 250mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

GMP Standard

Enandrol 250mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Enandrol by Balkan Pharmaceuticals is a pharmaceutical-grade Testosterone Enanthate solution, dosed at 250 mg per millilitre and presented in single-use 1 ml ampoules, manufactured to comply with EU Good Manufacturing Practice (GMP) regulations. Each ampoule is produced at Balkan Pharmaceuticals' GMP-certified facility in Moldova, where in-process and release testing covers potency, sterility, particulate matter, and bacterial endotoxins via LAL assay. Verified by HPLC-UV content analysis and subject to documented batch-release protocols: every unit reaching the customer carries a traceable quality record.

€38.00

Testoviron Depot 250mg/ml 1x1ml Ampoules by Schering

High Concentration

Testoviron Depot 250mg/ml 1x1ml Ampullen by Schering

Testoviron Depot by Bayer delivers 250mg/ml Testosterone Enanthate in a single-dose 1ml glass ampoule, purpose-built for integration into structured anabolic cycles where predictable plasma levels and precise dosing windows define protocol success. Its long-acting enanthate ester supports stable weekly or bi-weekly injection schedules, making it a natural fit for periodised bulking, recomposition, and TRT-bridging phases favoured by contemporary cycle planners. Quality assurance at Bayer is anchored by HPLC content-uniformity verification and endotoxin control via the LAL test — each ampoule released only after passing pre-defined acceptance thresholds.

€4.00

Season Highlight

Etho-Testosterone 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Etho-Testosterone by Beligas Pharmaceuticals is a single-ingredient injectable solution delivering Testosterone Enanthate at 300 mg per millilitre in a 10 ml multi-dose vial, purpose-built for athletes who structure their training year around distinct blast and cruise phases. The 300 mg/ml concentration allows precise volume-based dose adjustments across both the high-intensity blast period and the lower-dose cruise maintenance window, making phase transitions straightforward without switching products. Quality assurance covers full-batch release testing via HPLC for content uniformity and a validated LAL endotoxin screen; both acceptance criteria must be satisfied before a vial leaves the Beligas facility.

€38.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00